Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.75 |
| ▸ | F2 | P00734 | 6/20 | 0.75 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541837 | 0.99 | F10 (0.77) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL16730534 | 0.96 | F10 (0.72) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL18745678 | 0.91 | F10 (0.65) | F10F2SLC29A1 | |
| SCHEMBL16730419 | 0.91 | F10 (0.64) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL17690028 | 0.90 | F10 (0.77) | F10F2SLC29A1 | |
| SCHEMBL16730426 | 0.90 | F10 (0.64) | F10F2SLC29A1 | |
| SCHEMBL15731770 | 0.90 | F10 (0.62) | F10F2SLC29A1PDE4APDE4B | |
| SCHEMBL23777828 | 0.90 | F10 (0.82) | F10F2SLC29A1 | |
| SCHEMBL15883174 | 0.90 | F10 (0.82) | F10F2SLC29A1 | |
| SCHEMBL15628286 | 0.90 | F10 (0.63) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190111-B1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| EP-3190111-B1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| EP-3190111-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
| EP-3190111-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | F10 10/4885F2 3/4885SLC29A1 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.